News

Learn how analytics can be leveraged to hyper-target members for health reminders.

In an effort to lower prescription drug prices, CMS unveiled proposed polices for 2020 to strengthen and modernize the Medicare Part C and D programs. Here’s a closer look at what CMS’ provisions entail and how they help accomplish the Administration’s four strategies.

Medicare Advantage enrollees can expect new benefits with the start of 2019. Here's what healthcare executives should know.

Two major drug recalls in the last week include an expanded recall of a widely used blood pressure medication as well as over-the-counter infant ibuprofen.

Find out how healthcare organizations and analysts feel about new Medicare Part D proposals and drug pricing.

Managed Healthcare Executive polled executives from across the industry to see how they feel about the current state-and future of-healthcare. 

While healthcare is often taken for granted in urban communities, many rural populations struggle to access care. Here’s how one healthcare organization addresses rural impediments and their effects on health.

Here’s how experts predict healthcare will unfold in 2019.

The combination of one of the country’s largest insurers and one of the country’s largest pharmacy chains will dramatically reshape the healthcare industry.

The Integrated COPD Care Initiative in Alabama aims to reduce hospital readmission rates and acute to post-acute care-associated costs in COPD patients. Here are the results so far and insight from one of the program’s leaders.

FDA approved the first biosimilar to rituximab (Rituxan, Genentech) to treat non-Hodgkin lymphoma.

Evidence grows that these nonclinical factors have a large influence on patient outcomes. Here’s what hospitals and payers can do about it.

Here are ways healthcare execs can increase cancer awareness efforts.

A Managed Healthcare Executive’s cancer management survey revealed support for the selected use of complementary and alternative medicine. Where do things stand in what some consider a promising treatment area?

COPD is a chronic, progressive disorder that can lead to early death. Here are some ways to help mitigate the risk of developing this debilitating disorder.

The biosimilar market is flourishing in Europe-why aren’t we seeing similar gains in the U.S.?

As we look to the next year we can expect to see a few of these challenges settle, while others will continue to make headlines. Here are three things healthcare executives should watch.

In these arrangements, drug companies must partially reimburse insurers if the drug fails to earn its keep. Will COPD drugs be included in such arrangements?

The books healthcare executives recommend to other healthcare executives.

Despite a scolding from President Trump over drug price hikes, drug giant Pfizer announced it will raise the prices of 41 medications in January. That’s 10% of its entire drug portfolio.

FDA approved an autoinjector to treat rheumatoid arthritis and other diseases. 

Here are five things managed care executives should know about the proposed plan.

While some pharma makers have lowered drug prices and Express Scripts is pushing more branded manufacturers to lower list prices with its new National Preferred Flex Formulary, some manufacturers are raising drug prices.

Express Scripts’ new National Preferred Flex Formulary, which offers lower list prices on certain branded drugs, is a novel way to encourage pharma makers to lower prices.

Coming up with the benchmarks for measuring and rewarding quality and efficiency and finding the right provider partner are only part of the battle. Don’t forget about compliance with state and federal requirements. 

Frail patients are a  forgotten patient group-here’s how they were left behind and what can be done about it.

The value and benefits of biosimilars are increasingly becoming more apparent. Here are four areas where they are growing the most.